Investigational Drug Details
| Drug ID: | D336 |
| Drug Name: | Silymarin |
| Synonyms: | 822i9lej7s; Cardui Mariae Fructus; Carduus Marianus; Carduus Marianus Preparation; Carduus Marianus Seed; Fruit of Silybum Marianum; Holy Thistle Seed; Lady's Thistle Seed; Mariana Mariana Seed; Mary's Thistle Seed; Milk Thistle Extract; Milk Thistle Fruit; Milk Thistle Seed; Milk Thistle Seed Extract; Milk Thistle Silymarin; Milkthistle Fruit (Silybum Marianum L. Gaertner); Saint Mary's Thistle Extract; Shuifeiji; Silybi Fructus; Silybi Mariani Fructus (Silybum Marianum L. Gaertner); Silybum Marianum Dry Fruit; Silybum Marianum Dry Fruit Extract; Silybum Marianum Extract; Silybum Marianum Fruit; Silybum Marianum Fruit Extract; Silybum Marianum Seed; Silybum Marianum Seed Extract |
| Type: | Biological drug |
| DrugBank ID: | DB14375 |
| DrugBank Description: | Milk thistle is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. |
| PubChem ID: | 5213 |
| CasNo: | 65666-07-1 |
| Repositioning for NAFLD: | No |
| SMILES: | O1C(C(Oc2c1cc(C1Oc3c(C(=O)C1O)c(O)cc(O)c3)cc2)CO)c1cc(OC)c(O)cc1 |
| Structure: |
|
| InChiKey: | SEBFKMXJBCUCAI-UHFFFAOYSA-N |
| Molecular Weight: | 482.441 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | Antiviral; Antioxidant; Antifibrotic; Anti-inflammatory |
| Clinical Trial Progress: | Phase 3 on-going (IRCT20081110001444N6) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0005 | NCT02006498 | Phase 2 | Completed | No Results Available | June 2012 | January 8, 2016 | Details |
| L0060 | NCT05042245 | Phase 4 | Recruiting | No Results Available | April 26, 2019 | September 21, 2021 | Details |
| L0100 | NCT00389376 | Phase 1 | Completed | No Results Available | November 2006 | February 20, 2008 | Details |
| L0458 | IRCT20190602043787N1 | Phase 2/Phase 3 | Recruiting | No Results Available | 09/08/2019 | 7 October 2019 | Details |
| L0525 | IRCT2016111322869N2 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 30/08/2017 | 22 February 2018 | Details |
| L0563 | NCT02973295 | Phase 4 | Not recruiting | No Results Available | 04/11/2016 | 12 December 2020 | Details |
| L0583 | IRCT2016040727265N1 | Phase 3 | Not Recruiting | No Results Available | 29/05/2016 | 22 February 2018 | Details |
| L0614 | IRCT2015012520781N1 | Not applicable | Not Recruiting | No Results Available | 04/04/2015 | 22 February 2018 | Details |
| L0699 | IRCT138902253933N1 | Not applicable | Not Recruiting | No Results Available | 01/01/1900 | 22 February 2018 | Details |
| L0722 | IRCT20081110001444N6 | Phase 3 | Not Recruiting | No Results Available | 02/11/2019 | 5 November 2019 | Details |
| L0754 | CTRI/2019/04/018550 | Not applicable | Not Recruiting | No Results Available | 10/04/2019 | 24 November 2021 | Details |
| L0784 | NCT03749070 | Not applicable | Recruiting | No Results Available | 28/10/2018 | 7 February 2022 | Details |
| L0797 | IRCT20121105011375N5 | Not applicable | Recruiting | No Results Available | 10/05/2018 | 18 June 2018 | Details |
| L0818 | SLCTR/2017/016 | Not applicable | Recruiting | No Results Available | 19/06/2017 | 7 February 2022 | Details |
| L0840 | IRCT2016080614882N4 | Not applicable | Not Recruiting | No Results Available | 17/09/2016 | 22 February 2018 | Details |
| L0954 | IRCT201105084849N2 | Phase 3 | Not Recruiting | No Results Available | 28/05/2011 | 22 February 2018 | Details |
| L0975 | NCT00680407 | Phase 2 | Not recruiting | Has Results | 15/05/2008 | 12 December 2020 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00243 | 35170400 | Bioengineered | Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification. | Details |
| A01214 | 34827721 | Biomolecules | The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease. | Details |
| A01923 | 34560694 | Eur J Gastroenterol Hepatol | Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. | Details |
| A02313 | 34423182 | ACS Omega | Effect of Silymarin and Quercetin in a Miniaturized Scaffold in Wistar Rats against Non-alcoholic Fatty Liver Disease. | Details |
| A02443 | 34370218 | Clin J Gastroenterol | Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis. | Details |
| A02905 | 34201527 | Antioxidants (Basel) | Ethyl Acetate Fraction of Amomum villosum var. xanthioides Attenuates Hepatic Endoplasmic Reticulum Stress-Induced Non-Alcoholic Steatohepatitis via Improvement of Antioxidant Capacities. | Details |
| A03200 | 34092291 | Chin J Nat Med | Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. | Details |
| A03906 | 33824122 | Pak J Pharm Sci | Antioxidant characteristics and hepatoprotective effects of a formula derived from Maydis stigma, Nelumbo nucifera and Taraxacum officinale against carbon tetrachloride-induced hepatic damage in rats. | Details |
| A04028 | 33785007 | BMC Complement Med Ther | Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats. | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | Details |
| A04097 | 33761646 | Medicine (Baltimore) | The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. | Details |
| A04471 | 33603899 | Maedica (Bucur) | Triple Antioxidant Therapy, an Alternative for Patients with Chronic Liver Disease - A Prospective Multicenter Interventional Study. | Details |
| A04524 | 33587330 | Phytother Res | Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions. | Details |
| A04670 | 33546130 | Nutrients | Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. | Details |
| A04735 | 33520810 | J Diabetes Metab Disord | Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. | Details |
| A04829 | 33491528 | J Diet Suppl | The Effects of Vitamin E, Silymarin and Carnitine on the Metabolic Abnormalities Associated with Nonalcoholic Liver Disease. | Details |
| A05001 | 33418491 | Nutrition | Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. | Details |
| A05903 | 33080906 | Medicina (Kaunas) | Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. | Details |
| A06217 | 32964201 | JHEP Rep | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. | Details |
| A06327 | 32927776 | Nutrients | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. | Details |